Pathogenic PTCD1 variants cause mitochondrial protein aggregation and cardiomyopathy

Technical Summary: Pathogenic PTCD1 Variants Cause Mitochondrial Protein Aggregation and Cardiomyopathy

Problem Statement
Disorders affecting mitochondrial oxidative phosphorylation and multiple respiratory chain complexes represent a significant cause of human mitochondrial disease. However, the prevailing view that impaired energy metabolism alone dictates tissue-specific vulnerability and disease progression is insufficient. There is a recognized gap in understanding the additional molecular mechanisms that contribute to pathology in these conditions, particularly in post-mitotic tissues such as the heart. While PTCD1 variants had been previously identified in a child with infantile cardiomyopathy and combined respiratory chain deficiency, the specific pathogenic mechanisms linking PTCD1 deficiency to tissue damage remained to be fully elucidated.

Methodology
The study employed a multi-faceted approach combining human genetics, tissue characterization, and cellular modeling:

• Genetic Analysis: The authors investigated three specific PTCD1 (NM_015545.4) variants. They established the segregation pattern, noting that p.(Arg113Trp) and p.(Gly184Arg) occur in cis, while p.(Arg30*) is present in trans.
• Patient Tissue Characterization: Cardiac tissue from the affected patient was analyzed to assess mitochondrial function and protein homeostasis.
• Cellular Modeling: Cell models were engineered to express individual and combined PTCD1 missense variants to recapitulate the patient's genotype.
• Proteomics and Imaging: These models were subjected to proteomic analysis to identify aggregation patterns. Additionally, mitochondrial network morphology and OPA1 processing were examined to assess structural consequences.

Key Results

• Proteostasis Disruption: The study demonstrates that PTCD1 deficiency leads to disrupted mitochondrial proteostasis. Patient cardiac tissue exhibited impaired mitoribosome biogenesis, which was directly linked to the increased aggregation of selective mitochondrial matrix proteins.
• Variant Severity: In cell models, the combination of the cis p.(Arg113Trp) and p.(Gly184Arg) variants produced the most severe protein aggregation effects, recapitulating the pathology observed in the patient.
• Structural Consequences: The accumulation of protein aggregates was accompanied by altered OPA1 processing and significant remodeling of the mitochondrial network.
• Pathogenic Confirmation: The segregation of the identified variants and the functional data confirm their pathogenicity, establishing a direct link between PTCD1 loss and the observed cardiomyopathy.

Significance and Claims
The paper establishes that accumulating proteotoxic stress, arising specifically from impaired mitoribosome assembly, is a distinct pathogenic mechanism driving PTCD1-associated cardiomyopathy in post-mitotic tissues. The findings suggest that tissue damage in PTCD1 deficiency is not solely a consequence of respiratory chain failure or energy deficits but is significantly driven by the failure to maintain mitochondrial protein homeostasis. This work broadens the understanding of mitochondrial disease mechanisms by highlighting protein aggregation and mitoribosome biogenesis defects as critical contributors to tissue vulnerability.